Amphastar Pharmaceuticals Profit Margin 2012-2019 | AMPH

Current and historical gross margin, operating margin and net profit margin for Amphastar Pharmaceuticals (AMPH) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Amphastar Pharmaceuticals net profit margin as of September 30, 2019 is 15.77%.
Amphastar Pharmaceuticals Annual Profit Margins
Amphastar Pharmaceuticals Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.893B $0.295B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $61.086B 11.14
Teva Pharmaceutical Industries (TEVA) Israel $10.724B 4.36
Bausch Health Cos (BHC) Canada $10.203B 6.73
Mylan (MYL) United States $9.755B 4.38
Dr Reddy's Laboratories (RDY) India $6.645B 17.43
ASPEN PHARMACR (APNHY) South Africa $3.470B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.152B 11.15
Homology Medicines (FIXX) United States $0.783B 0.00
Voyager Therapeutics (VYGR) United States $0.509B 0.00
Akorn (AKRX) United States $0.462B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.431B 0.00
Assembly Biosciences (ASMB) United States $0.417B 0.00
Mallinckrodt Public (MNK) United Kingdom $0.284B 0.39
Adamas Pharmaceuticals (ADMS) United States $0.182B 0.00
Sol-Gel Technologies (SLGL) Israel $0.170B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.131B 0.00
CymaBay Therapeutics (CBAY) United States $0.114B 0.00
Teligent (TLGT) United States $0.034B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00